title: Newer agents for the management of overactive bladder.
abstract: The anticholinergics tolterodine and oxybutynin are well established in the management of overactive bladder. However, their activity at muscarinic receptors distant from the target site (i.e., bladder) produces anticholinergic side effects leading to poor tolerability. In 2004, trospium, solifenacin, and darifenacin were approved by the U.S. Food and Drug Administration for the treatment of overactive bladder. Trospium is water soluble and therefore is less likely to enter the central nervous system, and solifenacin and darifenacin are more selective for the bladder than older agents. Although these attributes could improve tolerability, clinical trials comparing relevant agents to validate this are lacking. Trials have shown that these newer agents decrease the frequency of incontinence episodes, the number of voids per day, and the number and severity of urgency episodes compared with placebo. These agents also have been shown to improve quality of life in women with overactive bladder and urinary incontinence. Head-to-head studies of the newer agents and immediate-release oxybutynin and tolterodine have suggested similar effectiveness across the class, although the newer agents are better tolerated. Trospium and darifenacin have not been compared with extended-release formulations of tolterodine or oxybutynin, which are better tolerated than the immediate-release versions. In one study, solifenacin produced a somewhat greater decrease in the number of incontinence episodes than extended-release tolterodine, with no difference in tolerability. In general, the newer agents appear to be at least as effective as their predecessors, although it is unclear whether they are better tolerated. Important pharmacokinetic differences among the agents (e.g., route of elimination) allow for selection of an appropriate agent based on individual factors such as cost and tolerability.
authors.affiliation: University of Florida, Gainesville, Florida, USA. epstein@cop.ufl.edu
authors.forename: Benjamin J
authors.initials: BJ
authors.lastname: Epstein
authors.forename: John G
authors.initials: JG
authors.lastname: Gums
authors.forename: Emerson
authors.initials: E
authors.lastname: Molina
mesh_terms: D006801:Humans; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D009119:Muscle Contraction / Q000502:physiology; D017773:Pelvic Floor / Q000502:physiology; D053201:Urinary Bladder, Overactive / Q000503:physiopathology / Q000628:therapy*
chemical_list: D018727:Muscarinic Antagonists